The estimated Net Worth of Dean L Schorno is at least $6.08 Million dollars as of 2 February 2024. Mr Schorno owns over 12,628 units of Rigel Pharmaceuticals stock worth over $5,225,496 and over the last 14 years he sold RIGL stock worth over $267,305. In addition, he makes $589,366 as Exec. VP & CFO at Rigel Pharmaceuticals.
Mr has made over 25 trades of the Rigel Pharmaceuticals stock since 2011, according to the Form 4 filled with the SEC. Most recently he sold 12,628 units of RIGL stock worth $14,396 on 2 February 2024.
The largest trade he's ever made was buying 50,000 units of Rigel Pharmaceuticals stock on 22 May 2019 worth over $106,500. On average, Mr trades about 2,498 units every 96 days since 2011. As of 2 February 2024 he still owns at least 402,891 units of Rigel Pharmaceuticals stock.
You can see the complete history of Mr Schorno stock trades at the bottom of the page.
Dean L. Schorno CPA is the Exec. VP & CFO at Rigel Pharmaceuticals.
As the Exec. VP & CFO of Rigel Pharmaceuticals, the total compensation of Mr CPA at Rigel Pharmaceuticals is $589,366. There are 4 executives at Rigel Pharmaceuticals getting paid more, with David A. Santos having the highest compensation of $1,034,977.
Mr CPA is 58, he's been the Exec. VP & CFO of Rigel Pharmaceuticals since . There are 2 older and 3 younger executives at Rigel Pharmaceuticals. The oldest executive at Rigel Pharmaceuticals is Raul R. Rodriguez, 60, who is the Pres, CEO & Director.
Dean's mailing address filed with the SEC is RIGEL PHARMACEUTICALS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 21 years, insiders at Rigel Pharmaceuticals have traded over $170,041,384 worth of Rigel Pharmaceuticals stock and bought 2,068,700 units worth $7,281,949 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Ansbert Gadicke, and Partners L P/Ilbiotechnolog.... On average, Rigel Pharmaceuticals executives and independent directors trade stock every 46 days with the average trade being worth of $961,207. The most recent stock trade was executed by David A Santos on 2 February 2024, trading 14,519 units of RIGL stock currently worth $16,552.
rigel pharmaceuticals, inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.
Rigel Pharmaceuticals executives and other stock owners filed with the SEC include: